Hyperforin modulates MAPK/CCL11 signaling to reduce the inflammatory response of nasal mucosal epithelial cells caused by allergic rhinitis by targeting BCL6

Xu,Chen; Su,Wen

doi:10.3892/etm.2023.12278

Hyperforin modulates MAPK/CCL11 signaling to reduce the inflammatory response of nasal mucosal epithelial cells caused by allergic rhinitis by targeting BCL6

Authors:
- Chen Xu
- Wen Su
View Affiliations

Affiliations: Department of Pediatrics, Wuhan Hospital of Integrated Traditional Chinese and Western Medicine (Wuhan No. 1 Hospital), Wuhan, Hubei 430022, P.R. China
Published online on: October 27, 2023 https://doi.org/10.3892/etm.2023.12278
Article Number: 579
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hyperforin is a type of bicyclic tetraketone with four isoprenoid chains extracted from Hypericum perforatum L. that has multiple biological activities such as anti‑diabetes, antitumor and anti‑inflammation. However, the role and potential mechanism of hyperforin in allergic rhinitis (AR) remains to be clarified. In the present study, cell viability was analyzed using Cell Counting Kit‑8 assay, while inflammation was detected using ELISA and reverse transcription‑quantitative PCR. Epithelial cell barrier damage was measured using western blotting and immunofluorescence staining. The expression levels of B‑cell lymphoma 6 (BCL6) and the p38 MAPK/C‑C motif chemokine 11 (CCL11) pathway were detected using western blotting. In addition, the association between hyperforin and BCL6 was analyzed by SWISS TargetPrediction, DisGeNET, Gene Ontology and Pathway databases. Molecular docking was performed using AutoDockTools 1.5.6 and Discovery Studio 4.5 software. The data demonstrated that there were 16 interlinking target genes of hyperforin with AR, in which BCL6 was the most relevant one with hyperforin in AR. The binding between hyperforin and BCL6 was verified, and molecular docking was modeled. The results revealed that hyperforin inhibited IL‑13‑induced nasal epithelial inflammatory cytokine release and repressed the damage to the cellular barrier from IL‑13 stimulation. In addition, hyperforin activated BCL6 expression and significantly suppressed the expression of p38 MAPK/CCL11. Silencing of BCL6 reversed the effects of hyperforin on IL‑13‑induced inflammation and barrier damage. In summary, the present results revealed that hyperforin suppressed IL‑13‑induced nasal epithelial cell inflammation and barrier damage by targeting BCL6/p38 MAPK/CCL11, which may provide promising therapeutic targets for AR.

View Figures

View References

1	Schuler Iv CF and Montejo JM: Allergic rhinitis in children and adolescents. Pediatr Clin North Am. 66:981–993. 2019.PubMed/NCBI View Article : Google Scholar
2	Schuler Iv CF and Montejo JM: Allergic rhinitis in children and adolescents. Immunol Allergy Clin North Am. 41:613–625. 2021.PubMed/NCBI View Article : Google Scholar
3	Hoyte FCL and Nelson HS: Recent advances in allergic rhinitis. F1000Res. 7(1333)2018.PubMed/NCBI View Article : Google Scholar
4	Siddiqui ZA, Walker A, Pirwani MM, Tahiri M and Syed I: Allergic rhinitis: Diagnosis and management. Br J Hosp Med (Lond). 83:1–9. 2022.PubMed/NCBI View Article : Google Scholar
5	Incorvaia C, Cavaliere C, Frati F and Masieri S: Allergic rhinitis. J Biol Regul Homeost Agents. 32 (1 Suppl 1):S61–S66. 2018.PubMed/NCBI
6	Meng Y, Wang C and Zhang L: Advances and novel developments in allergic rhinitis. Allergy. 75:3069–3076. 2020.PubMed/NCBI View Article : Google Scholar
7	Ghezzi M, Pozzi E, Abbattista L, Lonoce L, Zuccotti GV and D'Auria E: Barrier impairment and Type 2 inflammation in allergic diseases: The pediatric perspective. Children (Basel). 8(1165)2021.PubMed/NCBI View Article : Google Scholar
8	Liu S, Yu B, Dai J and Chen R: Targeting the biological activity and biosynthesis of hyperforin: A mini-review. Chin J Nat Med. 20:721–728. 2022.PubMed/NCBI View Article : Google Scholar
9	Li XX, Yan Y, Zhang J, Ding K, Xia CY, Pan XG, Shi YJ, Xu JK, He J and Zhang WK: Hyperforin: A natural lead compound with multiple pharmacological activities. Phytochemistry. 206(113526)2023.PubMed/NCBI View Article : Google Scholar
10	Wu S, Malaco Morotti AL, Wang S, Wang Y, Xu X, Chen J, Wang G and Tatsis EC: Convergent gene clusters underpin hyperforin biosynthesis in St John's wort. New Phytol. 235:646–661. 2022.PubMed/NCBI View Article : Google Scholar
11	Novelli M, Masiello P, Beffy P and Menegazzi M: Protective role of St. John's wort and its components hyperforin and hypericin against diabetes through inhibition of inflammatory signaling: Evidence from in vitro and in vivo studies. Int J Mol Sci. 21(8108)2020.PubMed/NCBI View Article : Google Scholar
12	Nawrot J, Gornowicz-Porowska J, Budzianowski J, Nowak G, Schroeder G and Kurczewska J: Medicinal herbs in the relief of neurological, cardiovascular, and respiratory symptoms after COVID-19 infection a literature review. Cells. 11(1897)2022.PubMed/NCBI View Article : Google Scholar
13	Zhang S, Zhang J, Yu J, Chen X, Zhang F, Wei W, Zhang L, Chen W, Lin N and Wu Y: Hyperforin ameliorates imiquimod-induced psoriasis-like murine skin inflammation by modulating IL-17A-producing γδ T cells. Front Immunol. 12(635076)2021.PubMed/NCBI View Article : Google Scholar
14	Lemmen J, Tozakidis IE and Galla HJ: Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res. 1491:1–13. 2013.PubMed/NCBI View Article : Google Scholar
15	Wang B, Gao Y, Zheng G, Ren X, Sun B, Zhu K, Luo H, Wang Z and Xu M: Platycodin D inhibits interleukin-13-induced the expression of inflammatory cytokines and mucus in nasal epithelial cells. Biomed Pharmacother. 84:1108–1112. 2016.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Kakli HA and Riley TD: Allergic rhinitis. Prim Care. 43:465–475. 2016.PubMed/NCBI View Article : Google Scholar
18	Campo P, Eguiluz-Gracia I, Bogas G, Salas M, Plaza Serón C, Pérez N, Mayorga C, Torres MJ, Shamji MH and Rondon C: Local allergic rhinitis: Implications for management. Clin Exp Allergy. 49:6–16. 2019.PubMed/NCBI View Article : Google Scholar
19	Zhang Y, Lan F and Zhang L: Advances and highlights in allergic rhinitis. Allergy. 76:3383–3389. 2021.PubMed/NCBI View Article : Google Scholar
20	Beken B, Eguiluz-Gracia I, Yazıcıoğlu M and Campo P: Local allergic rhinitis: A pediatric perspective. Turk J Pediatr. 62:701–710. 2020.PubMed/NCBI View Article : Google Scholar
21	Wang L, Lv Q, Song X, Jiang K and Zhang J: ADRB2 suppresses IL-13-induced allergic rhinitis inflammatory cytokine regulated by miR-15a-5p. Hum Cell. 32:306–315. 2019.PubMed/NCBI View Article : Google Scholar
22	Teng Y, Zhang R, Liu C, Zhou L, Wang H, Zhuang W, Huang Y and Hong Z: miR-143 inhibits interleukin-13-induced inflammatory cytokine and mucus production in nasal epithelial cells from allergic rhinitis patients by targeting IL13Rα1. Biochem Biophys Res Commun. 457:58–64. 2015.PubMed/NCBI View Article : Google Scholar
23	Novelli M, Menegazzi M, Beffy P, Porozov S, Gregorelli A, Giacopelli D, De Tata V and Masiello P: St. John's wort extract and hyperforin inhibit multiple phosphorylation steps of cytokine signaling and prevent inflammatory and apoptotic gene induction in pancreatic β cells. Int J Biochem Cell Biol. 81:92–104. 2016.PubMed/NCBI View Article : Google Scholar
24	Pavón-Romero GF, Parra-Vargas MI, Ramírez-Jiménez F, Melgoza-Ruiz E, Serrano-Pérez NH and Teran LM: Allergen immunotherapy: Current and future trends. Cells. 11(212)2022.PubMed/NCBI View Article : Google Scholar
25	Meinke MC, Schanzer S, Haag SF, Casetti F, Müller ML, Wölfle U, Kleemann A, Lademann J and Schempp CM: In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity in vitro and ex vivo. Eur J Pharm Biopharm. 81:346–350. 2012.PubMed/NCBI View Article : Google Scholar
26	Takada H, Yonekawa J, Matsumoto M, Furuya K and Sokabe M: Hyperforin/HP-β-cyclodextrin enhances mechanosensitive Ca²⁺ signaling in HaCaT keratinocytes and in atopic skin ex vivo which accelerates wound healing. Biomed Res Int. 2017(8701801)2017.PubMed/NCBI View Article : Google Scholar
27	Brondz I: Super antibiotics, part II. Hyperforin, mass spectroscopy (MS) and gas chromatography-mass spectrometry (GC-MS), evidence of permeability of the blood-testis barrier (BTB) and the blood-brain barrier (BBB) to hyperforin. Int J Anal Mass Spectrom Chromatogr. 4:66–73. 2016.
28	Marrelli M, Statti G, Conforti F and Menichini F: New potential pharmaceutical applications of hypericum species. Mini Rev Med Chem. 16:710–720. 2016.PubMed/NCBI View Article : Google Scholar
29	Chen D, Xiong XQ, Zang YH, Tong Y, Zhou B, Chen Q, Li YH, Gao XY, Kang YM and Zhu GQ: BCL6 attenuates renal inflammation via negative regulation of NLRP3 transcription. Cell Death Dis. 8(e3156)2017.PubMed/NCBI View Article : Google Scholar
30	Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, et al: EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis. Cancer Cell. 30:197–213. 2016.PubMed/NCBI View Article : Google Scholar
31	Peng Y, Li XQ and Qiu QH: Detection of differentially expressed gene of allergic rhinitis based on RT² profiler PCR array. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 31:869–872. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
32	Gu Y, Luo M, Li Y, Su Z, Wang Y, Chen X, Zhang S, Sun W and Kong X: Bcl6 knockdown aggravates hypoxia injury in cardiomyocytes via the P38 pathway. Cell Biol Int. 43:108–116. 2019.PubMed/NCBI View Article : Google Scholar
33	Long S and Zhang H: MIR-181A-5P attenuates ovalbumin-induced allergic inflammation in nasal epithelial cells by targeting IL-33/P38 MAPK pathway. Clin Invest Med. 44:E31–E38. 2021.PubMed/NCBI View Article : Google Scholar
34	Roh KB, Jung E, Park D and Lee J: Fumaric acid attenuates the eotaxin-1 expression in TNF-α-stimulated fibroblasts by suppressing p38 MAPK-dependent NF-κB signaling. Food Chem Toxicol. 58:423–431. 2013.PubMed/NCBI View Article : Google Scholar
35	Park JY, Choi JH, Lee SN, Cho HJ, Ahn JS, Kim YB, Park DY, Park SC, Kim SI, Kang MJ, et al: Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines. J Allergy Clin Immunol. 147:1720–1731. 2021.PubMed/NCBI View Article : Google Scholar